Sign up to save your podcasts
Or
Share Mepolizumab and the treatment of chronic rhinosinusitis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Mepolizumab and the treatment of chronic rhinosinusitis
Dr. Joseph Han discusses the results of the phase III SYNAPSE trial, evaluating the efficacy and safety of mepolizumab in patients with chronic rhinosinusitis.
Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00097-7/fulltext
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet Group
5
11 ratings
Dr. Joseph Han discusses the results of the phase III SYNAPSE trial, evaluating the efficacy and safety of mepolizumab in patients with chronic rhinosinusitis.
Read the full article:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00097-7/fulltext
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet Respiratory Medicine in conversation with
View all
JAMA Editors' Summary
140 Listeners
Annals of Internal Medicine Podcast
135 Listeners
NEJM This Week
324 Listeners
JAMA Clinical Reviews
498 Listeners
CHEST Journal Podcasts
64 Listeners
Diabetes Core Update
101 Listeners
Out of the Blue: An AJRCCM Podcast
37 Listeners
ERS Publications Podcasts
6 Listeners
Health Report
131 Listeners
The Daily
112,543 Listeners
BMJ Best Practice Podcast
20 Listeners
Core IM | Internal Medicine Podcast
1,144 Listeners
The Lancet Voice
21 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Oncology in conversation with
1 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet in conversation with
0 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
eBioMedicine in conversation with
0 Listeners
In conversation with...
0 Listeners
PulmPEEPs
59 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
The Lancet Regional Health in conversation with
0 Listeners
The Lancet Primary Care in conversation with
0 Listeners
The Lancet Regional Health Americas in conversation with
0 Listeners